Tumor refractoriness to anti-VEGF treatment is mediated by CD11b +Gr1+ myeloid cells

Nature Biotechnology

Volumn 25, Issue 8, 2007, Pages 911-920

  Shojaei, Farbod ^a   Wu, Xiumin ^a   Malik, Ajay K ^a   Zhong, Cuiling ^a   Baldwin, Megan E ^a   Schanz, Stefanie ^a   Fuh, Germaine ^a   Gerber, Hans Peter ^a,b   Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY (MAB); MURINE CANCER MODELS; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

ANTIBODIES; GROWTH KINETICS; ONCOLOGY; PATIENT TREATMENT;

CELLS;

CD11B ANTIGEN; FLUOROURACIL; GEMCITABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G6.23; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GROWTH INHIBITION; IMMUNE SYSTEM; LEWIS CARCINOMA; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; LEUKEMIA, MYELOID; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 34547820876     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1323     Document Type: Article

References (50)

1. Longley, D.B. & Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292 (2005).
2. Hida, K. et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64, 8249-8255 (2004).
3. Pelham, R.J. et al. Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc. Natl. Acad. Sci. USA 103, 19848-19853 (2006).
4. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
5. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004).
6. Gerber, H.P. & Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680 (2005).
7. Casanovas, O., Hicklin, D.J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
8. Kerbel, R.S. et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20, 79-86 (2001).
9. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
10. Albini, A., Tosetti, F., Benelli, R. & Noonan, D.M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 65, 10637-10641 (2005).
11. Wald, M. et al. Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother. Pharmacol. 47 Suppl, S16-S22 (2001).
12. Ho, R.L. et al. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol. Res. 5, 363-372 (1993).
13. Liu, Y., Zhang, W., Chan, T., Saxena, A. & Xiang, J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res. 26, 757-763 (2002).
14. Bobek, V. et al. Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma. Clin. Exp. Metastasis 21, 705-708 (2004).
15. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407, 313-319 (1997).
16. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201 (2001).
17. Yang, L. et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004).
18. Morrison, S.J., Uchida, N. & Weissman, I.L. The biology of hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 11, 35-71 (1995).
19. Onai, N. et al. Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow-hematopoietic progenitor cells expressing SDF-1-intrakine. Blood 96, 2074-2080 (2000).
20. Kusmartsev, S. & Gabrilovich, D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51, 293-298 (2002).
21. Bronte, V. et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96, 3838-3846 (2000).
22. Hestdal, K. et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 147, 22-28 (1991).
23. Davis-Smyth, T., Chen, H., Park, J., Presta, L.G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919-4927 (1996).
24. Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4, 336-340 (1998).
25. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393-11398 (2002).
26. Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-3343 (1996).
27. Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8, 841-849 (2002).
28. Lazarovici, P., Gazit, A., Staniszewska, I., Marcinkiewicz, C. & Lelkes, P.I. Nerve growth factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane. Endothelium 13, 51-59 (2006).
29. Favre, C.J. et al. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am. J. Physiol. Heart Circ. Physiol. 285, H1917-H1938 (2003).
30. Good, D.J. et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628 (1990).
31. Palmer-Crocker, R.L., Hughes, C.C. & Pober, J.S. IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. J. Clin. Invest. 98, 604-609 (1996).
32. Roy, B. et al. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J. Leukoc. Biol. 72, 580-589 (2002).
33. Edfeldt, K., Swedenborg, J., Hansson, G.K. & Yan, Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161 (2002).
34. Rapoport, A.P., Abboud, C.N. & DiPersio, J.F. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Rev. 6, 43-57 (1992).
35. Lechmann, M., Berchtold, S., Hauber, J. & Steinkasserer, A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23, 273-275 (2002).
36. Feau, S. et al. Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice. Blood 105, 697-702 (2005).
37. Niess, J.H. et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307, 254-258 (2005).
38. Derynck, R., Akhurst, R.J. & Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129 (2001).
39. Leonard, E.J., Skeel, A., Yoshimura, T. & Rankin, J. Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes. Adv. Exp. Med. Biol. 351, 55-64 (1993).
40. Cook, D.N. The role of MIP-1 alpha in inflammation and hematopoiesis. J. Leukoc. Biol. 59, 61-66 (1996).
41. Dinarello, C.A. Blocking IL-1 in systemic inflammation. J. Exp. Med. 201, 1355-1359 (2005).
42. Lemoli, R.M. et al. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination. Leukemia 5, 386-391 (1991).
43. Ferrara, N., Hillan, K.J., Gerber, H.P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
44. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001).
45. Di Maio, M. et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 6, 669-677 (2005).
46. Liang, W.C. et al. Cross-species VEGF-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal vegf. J. Biol. Chem. 281, 951-961 (2006).
47. Dong, J. et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 23, 2800-2810 (2004).
48. Malik, A.K. et al. Redundant roles of VEGF-B and PIGF during selective VEGF-A blockade in mice. Blood 107, 550-557 (2006).
49. Gerber, H.P., Kowalski, J., Sherman, D., Eberhard, D.A. & Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253-6258 (2000).
50. Gerber, H.P. et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954-958 (2002).